Capmatinib is a selective MET inhibitor primarily used to treat metastatic non-small cell lung cancer with MET exon 14 skipping mutations. Its usage needs to be adjusted according to the individual situation of the patient, including routine dosage, medication for special populations, and precautions. It is necessary to strictly follow medical advice to ensure efficacy and safety.

1. Conventional usage

(1) Administration method: Oral administration, the whole tablet should be swallowed and not crushed or chewed.

(2) Medication frequency: twice a day (with an interval of about 12 hours), can be taken with meals or on an empty stomach.

(3) Standard dose: 400 milligrams per dose (200 milligrams per tablet x 2 tablets), with a total daily dose of 800 milligrams.

2. Usage for special populations

(1) Liver dysfunction: moderate damage (Child Pugh B grade) reduced to 200 milligrams per dose; Severe damage (Child Pugh C grade) is prohibited.

(2) Renal insufficiency: mild to moderate damage does not require adjustment; Data on end-stage renal disease or dialysis patients is limited and should be used with caution.

(3) Elderly patients: No need to adjust dosage, but close monitoring of adverse reactions is required.

3 Principles of Dose Adjustment

(1) First dose reduction: When intolerable toxicity occurs, reduce to 300 milligrams twice daily.

(2) Secondary reduction: If still intolerant, further reduce to 200 milligrams twice daily.

(3) Permanent discontinuation of medication: If the dosage is still intolerable or severe toxic reactions occur after reduction, the medication should be discontinued.

4 Medication precautions

(1) Omission treatment: If there is less than 4 hours before the next administration, it should be skipped and cannot be supplemented or double the dose.

(2) Drug interactions: Avoid co administration with strong CYP3A inducers; The combination with proton pump inhibitors requires a 2-hour interval.

(3) Monitoring requirements: Regularly check liver function, electrolytes, and electrocardiogram to be alert to the risk of interstitial lung disease.